JPMorgan downgraded Allogene Therapeutics (ALLO) to Underweight from Neutral without a price target The firm says the company’s decision to drop CD52’s component in the cema-cel program was “rational and truly unavoidable given the fatal event.” It believes adoption of cema-cel will take time, making it difficult to remain optimistic on the shares in the near-term.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
- Allogene Therapeutics Earnings Call: Progress Amid Challenges
- Allogene Therapeutics management to meet with Piper Sandler
- Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
- Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics